Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

With no family history of breast cancer, the thought of it wasn’t always present for longtime Winchester native Maureen ...

But sometimes, something goes wrong in the gene that controls the HER2 protein and your body makes too many of these receptors. This causes your breast cells to grow and divide uncontrollably.

The treatment combines a new drug, inavolisib, with two older breast cancer drugs, fulvestrant (Faslodex ®) and palbociclib (Ibrance ®) . Inavolisib, which targets PIK3CA mutations, appears to be a ...

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

The potential to treat GEA by targeting HER2 was confirmed in 2010 when researchers showed that adding Roche’s Herceptin to chemotherapy extended OS from 11.1 months to 13.8 months.

Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after ...

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...

Approval is based on Phase III INAVO120 results, showing the Itovebi™ (inavolisib)-based regimen more than doubled ...

The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.